Post-earnings recap
Reported
Tue, May 9, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock still dipped slightly by 0.17%, likely due to the lack of revenue information and forward guidance. Investors may be cautious as they await more clarity on the company's future performance and upcoming projects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | +2.72% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding their future projects. They emphasized the significance of their pipeline and upcoming trials.
Management expressed optimism about ongoing projects.
They highlighted the importance of upcoming clinical trials.